Trials / Completed
CompletedNCT05268991
Aging and Frailty Study
Aging Biomarkers, Geriatric Assessment and Electronic Frailty Index (AGE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.
Detailed description
Primary Objective: Describe mean and variation of the electronic frailty index-cancer, geriatric measures, patient reported outcomes, and biomarkers of aging of chemotherapy, and their change.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Geriatric Assessments and Frailty Indices | Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record |
Timeline
- Start date
- 2022-05-02
- Primary completion
- 2025-06-13
- Completion
- 2025-06-13
- First posted
- 2022-03-07
- Last updated
- 2025-08-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05268991. Inclusion in this directory is not an endorsement.